Erdafitinib manufacturer

Erdafitinib (Erdafitinib) is developed and produced by Janssen, a subsidiary of the US pharmaceutical company Johnson & Johnson. Erdafitinib is approved for the treatment of locally advanced or metastatic urothelial carcinoma. These patients have FGFR3/2 susceptibility changes and have progressed after platinum-containing chemotherapy.

Relevant data show that the overall survival rate of patients who receivederdafitinib was 12.1 months, while that of patients who received chemotherapy was 7.8 months. Erdafitinib is the active ingredient in BALVERSA and is a kinase inhibitor. The chemical name is N-(3, 5-dimethoxyphenyl)-N '-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazole-4-yl )quinoxaline-6-yl]ethane-1, 2-diamine. Erdafitinib is a yellow powder. It is almost insoluble, or insoluble, or easily soluble in organic solvents, and is slightly soluble, almost insoluble, or insoluble in aqueous media with various pH values. The molecular formula is C25H 30N 6O 2 and the molecular weight is 446.56.

ErdafitinibCommon side effects include increased phosphate levels, mouth sores, feeling tired, changes in kidney function, diarrhea, dry mouth, nail separation from the bed or poor nail formation, changes in liver function, low salt(sodium< span>) levels, decreased appetite, changes in taste, low red blood cells(anemia), dry skin, dry eyes, and hair loss. Other side effects include redness, swelling, peeling, or tenderness of the hands or feet(Hand-foot syndrome) , constipation, stomach pain, nausea, and muscle pain. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.